Unknown

Dataset Information

0

CD20-selective inhibition of CD47-SIRP? "don't eat me" signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab.

ABSTRACT: Here, we report on a novel bispecific antibody-derivative, designated RTX-CD47, with unique capacity for CD20-directed inhibition of CD47-SIRP? "don't eat me" signaling. RTX-CD47 comprises a CD20-targeting scFv antibody fragment derived from rituximab fused in tandem to a CD47-blocking scFv. Single agent treatment with RTX-CD47 triggered significant phagocytic removal of CD20pos/CD47pos malignant B-cells, but not of CD20neg/CD47pos cells, and required no pro-phagocytic FcR-mediated signaling. Importantly, treatment with RTX-CD47 synergistically enhanced the phagocytic elimination of primary malignant B cells by autologous phagocytic effector cells as induced by therapeutic anticancer antibodies daratumumab (anti-CD38), alemtuzumab (anti-CD52) and obinutuzumab (anti-CD20). In conclusion, RTX-CD47 blocks CD47 "don't eat me" signaling by cancer cells in a CD20-directed manner with essentially no activity towards CD20neg/CD47pos cells and enhances the activity of therapeutic anticancer antibodies directed to B-cell malignancies.

SUBMITTER: van Bommel PE 

PROVIDER: S-EPMC5749665 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

CD20-selective inhibition of CD47-SIRPα "don't eat me" signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab.

van Bommel Peter E PE   He Yuan Y   Schepel Ilona I   Hendriks Mark A J M MAJM   Wiersma Valerie R VR   van Ginkel Robert J RJ   van Meerten Tom T   Ammatuna Emanuele E   Huls Gerwin G   Samplonius Douwe F DF   Helfrich Wijnand W   Bremer Edwin E  

Oncoimmunology 20171031 2

Here, we report on a novel bispecific antibody-derivative, designated RTX-CD47, with unique capacity for CD20-directed inhibition of CD47-SIRPα "don't eat me" signaling. RTX-CD47 comprises a CD20-targeting scFv antibody fragment derived from rituximab fused in tandem to a CD47-blocking scFv. Single agent treatment with RTX-CD47 triggered significant phagocytic removal of CD20<sup>pos</sup>/CD47<sup>pos</sup> malignant B-cells, but not of CD20<sup>neg</sup>/CD47<sup>pos</sup> cells, and required  ...[more]

Similar Datasets

Unknown Blocking "don't eat me" signal of CD47-SIRPα in hematological malignancies, an in-depth review.
| S-EPMC6186508 | biostudies-literature
Unknown Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα "don't eat me" immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation.
| S-EPMC7714490 | biostudies-literature
Unknown SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the "don't eat me" signal and activating the "eat me" signal.
| S-EPMC9670587 | biostudies-literature
Unknown Prion pathogenesis is unaltered in the absence of SIRPα-mediated "don't-eat-me" signaling.
| S-EPMC5435345 | biostudies-literature
Unknown The CD47 "don't eat me signal" is highly expressed in human ovarian cancer.
| S-EPMC5077667 | biostudies-literature
Unknown Sodium stibogluconate and CD47-SIRPα blockade overcome resistance of anti-CD20-opsonized B cells to neutrophil killing.
| S-EPMC9006259 | biostudies-literature
Unknown Cancer Therapy Targeting CD47/SIRPα.
| S-EPMC8699673 | biostudies-literature
Unknown Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 "Don't Eat Me" Signals.
| S-EPMC4621226 | biostudies-literature
Unknown A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells.
| S-EPMC4623422 | biostudies-literature
Unknown CD47-SIRPα-targeted therapeutics: status and prospects.
| S-EPMC9216458 | biostudies-literature